

Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway

Berit Feiring,¹ Ida Laake,¹ Irene Kraus Christiansen,² Mona Hansen,² Jeanette Stålcrantz,³ Ole Herman Ambur,^{2,4,a} Per Magnus,⁵ Christine Monceyron Jonassen,⁶ and Lill Trogstad¹

¹Department of Infectious Disease Epidemiology and Modelling, Norwegian Institute of Public Health, Oslo, ²Department of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, ³Department of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, ⁴Department of Natural Sciences and Health, Oslo Metropolitan University, Oslo, ⁵Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, and ⁶Center for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway

Background. In 2009, quadrivalent human papillomavirus (HPV) vaccine was introduced in a school-based single-cohort program targeting 12-year-old girls in Norway. We estimated the impact of the Norwegian HPV immunization program.

Methods. Three birth cohorts of 17-year-old girls, 2 nonvaccine-eligible cohorts (born 1994 or 1996) and 1 vaccine-eligible cohort (born 1997) were invited to deliver urine samples. The samples were analyzed for 37 HPV genotypes. HPV prevalence was compared between birth cohorts and between vaccinated and unvaccinated girls within and across birth cohorts after linkage to the Norwegian Immunisation Registry.

Results. In total, 17 749 urine samples were analyzed. A 42% (95% confidence interval [CI], 37%–47%) reduction in any HPV type and 81% (95% CI, 76%–85%) reduction in vaccine types (HPV-6/11/16/18) were observed in the vaccine-eligible cohort compared to the 1994 cohort. Vaccine types were reduced by 54% (95% CI, 39%–66%) and 90% (95% CI, 86%–92%) in unvaccinated and vaccinated girls, respectively, from the 1997 cohort, compared with unvaccinated girls born in 1994. A significant reduction was also observed for several nonvaccine types. Vaccine-type prevalence was reduced by 77% (95% CI, 65%–85%) in vaccinated compared with unvaccinated girls from the 1997 cohort.

Conclusions. In this largely HPV-naïve population, we observed a substantial reduction in vaccine and nonvaccine types in vaccinated and unvaccinated girls following introduction of HPV vaccination.

Keywords. human papillomavirus; HPV vaccine; immunization program; effectiveness; vaccine impact.

Human papillomavirus (HPV) infection is the most common sexually transmitted infection. Based on the oncogenic potential, HPV genotypes are classified as high-risk (HR), probably/possibly HR, or undetermined or low-risk (LR) types [1]. HPV infection is the underlying cause of cervical and other anogenital cancers, as well as cancers in the oropharynx [1, 2]. HPV-16 and HPV-18 are responsible for 70%

of all cases of cervical cancer, whereas HPV-6 and HPV-11 cause 90% of genital warts [2].

In Norway, the HPV vaccine has been offered in a school-based immunization program with single-cohort delivery to 12-year-old girls since 2009. In contrast to most Western countries, no catch-up vaccination of older girls was initially offered.

Since the HPV vaccine was first introduced in national programs in 2007, several studies have described real-life effectiveness including reduction of precancerous cervical lesions among vaccinated women [3–7]. In addition to the direct effect against vaccine types, the population-level effectiveness will depend on cross-protection against nonvaccine types as well as the extent of herd protection achieved in a given setting. To our knowledge, previous effectiveness studies have only been performed in countries with catch-up vaccination. HPV vaccines are prophylactic and do not clear ongoing infections. In clinical trials in women aged 16–26 years, the efficacy of HPV vaccines is higher in HPV-naïve populations than in total vaccinated cohorts, reflecting the lack of protection against ongoing HPV infections [8, 9]. Thus, protection is likely to be less effective in older catch-up populations, in comparison to young and mostly

Received 24 April 2018; editorial decision 3 July 2018; accepted 12 July 2018; published online July 16, 2018.

Presented in part: European Research Organisation on Genital Infection and Neoplasia, Amsterdam, The Netherlands, 8–11 October 2017. Abstract 00476.

^aPresent affiliation: Department of Natural Sciences and Health, Oslo Metropolitan University, Norway.

Correspondence: B. Feiring, MScPharm, Department of Infectious Disease Epidemiology and Modelling, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213 Oslo, Norway (berit.feiring@fhi.no).

The Journal of Infectious Diseases® 2018;218:1900–10

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com DOI: 10.1093/infdis/jiy432

HPV-naive populations. Effectiveness data from school-based programs in countries with single-cohort delivery only have not been reported.

Three HPV vaccines including antigens from 2, 4, or 9 HPV types are currently licensed. The quadrivalent vaccine, including antigens against HPV-6/11/16/18, was used in Norway until 2017. The HPV vaccine uptake increased from 70% in the first birth cohort that was eligible for HPV vaccination (born in 1997) [10] to 89% among girls born in 2004 [11].

In Norway, organized cervical screening is not offered until the age of 25. Thus, screening data are not suitable to assess early vaccine impact. Consequently, a national HPV surveillance program comprising a series of nationwide, population-based cross-sectional studies was set up, assessing HPV prevalence in urine samples from girls and young women not yet targeted by the national screening program [12].

The aim of the current study was to assess the impact of the Norwegian school-based HPV immunization program, by comparing the HPV prevalence in urine samples from 17-year-old girls in 3 birth cohorts: the first vaccine-eligible cohort and 2 birth cohorts not eligible for routine HPV vaccination. We studied the direct effect in vaccinated individuals and the potential herd effect in nonvaccinated individuals. Furthermore, the cross-protective effect against nonvaccine types and possible type replacement were assessed. Finally, the total effectiveness of the program (direct plus indirect effects) was estimated.

METHODS

Inclusion and Sampling

Girls from 3 birth cohorts (1994, 1996, and 1997) were eligible for inclusion. Girls born in 1994 (baseline cohort) and 1996 were not eligible for HPV vaccination. Girls born in 1997 (vaccine cohort) were the first birth cohort eligible for HPV vaccination. The Norwegian Central Population Registry was used to obtain information on all girls in the 3 birth cohorts residing in Norway as of 1 February the year they turned 17 (2011, 2013, and 2014 for girls born in 1994, 1996, and 1997, respectively). Girls were invited by mail around their 17th birthday. Due to an administrative error, 5260 girls born in November/December 1994 were not invited. In total, 25 811 girls born in 1994, 31 749 girls born in 1996, and 31 389 girls born in 1997 were invited.

Upon informed consent, girls received a urine sampling kit and were asked to return a first-void urine sample to the Norwegian Institute of Public Health. The sample device contained boric acid to prevent bacterial growth. All samples were registered, aliquoted, and stored at -80°C prior to analysis at the Norwegian HPV Reference Laboratory at Akershus University Hospital. Participants received 2 cinema tickets as compensation. All samples received by 26 November 2014 were analyzed for HPV by 19 August 2015 and have been included in the statistical analyses.

The study was approved by the Regional Committee for Medical and Health Research Ethics, South East Norway and the Norwegian Data Protection Authority.

HPV Vaccination

Individual records on HPV vaccination were retrieved from the Norwegian Immunisation Registry. Notification of all vaccinations provided through the national childhood immunization program is mandatory without the need for consent [13]. HPV vaccinations provided outside the immunization program are notifiable, but the vaccinees or their parents/guardians may oppose notification. Thus, vaccination outside the program may be subject to some underreporting. However, the effect on our results is most likely negligible as only a total of 1000–2000 girls/women per year were prescribed HPV vaccine outside the immunization program from 2007 to 2014 [14].

Vaccine doses administered <15 days prior to urine sampling were unlikely to have a clinical impact and were not taken into account.

When comparing invited and participating girls, vaccine uptake was calculated as of 1 January the year of urine sampling for the respective birth cohorts.

Girls who had not received any doses of HPV vaccine were defined as unvaccinated, whereas girls who had received all 3 doses were defined as vaccinated. Partially vaccinated girls were excluded from analysis.

HPV Testing

DNA extraction and HPV genotyping were performed at the Norwegian HPV Reference Laboratory as previously described [12]. In brief, the presence of HPV DNA was investigated using a modified GP5⁺/GP6⁺ polymerase chain reaction (PCR) protocol [15], followed by Luminex-based genotype detection [16]. Sample adequacy was evaluated through a β -globin PCR assay. The assay detects 37 genotypes: 12 HR HPV types (HPV types 16/18/31/33/35/39/45/51/52/56/58/59), 1 probably HR type (HPV-68), 9 possibly HR types (HPV types 26/30/53/66/67/69/70/73/82), and 15 LR types (HPV types 6/11/40/42/43/54/61/74/81/83/86/87/89/90/91) [1]. The samples were analyzed consecutively with overlaps between birth cohorts, according to the same genotyping protocol.

The HPV prevalence data was linked to data from the Central Population Registry and to the immunization records, using the unique personal identifier allocated to all Norwegian citizens.

Statistical Analysis

We calculated the prevalence with corresponding 95% Wilson score confidence intervals (CIs) [17] for each individual HPV type and for the following combinations: “any HPV type,” “any HR type,” “any probably/possibly HR type,” “any LR type,” “vaccine types (HPV-6/11/16/18),” “HPV-16/18,” “HPV-6/11,” “any nonvaccine HR type,” “any HR type other than HPV-16/18/31/33/45,” “HPV-31/33/45 (HR types for which

cross-protection has been suggested),” “HPV-31/33/45/52/58 (additional HR types in the nonavalent vaccine),” “HPV-6/11/16/18/31/33/45/52/58” (nonavalent vaccine types), as well as for multiple HPV infection.

To compare HPV prevalence between groups, we calculated relative risks (RRs) with 95% Koopman CIs [18]. Girls born in 1996 and girls born in 1997 were compared to girls born in 1994 (baseline cohort). Girls born in 1997 were also compared to girls born in 1996. To estimate total effectiveness of the HPV immunization program (direct effect plus herd effect), we compared vaccinated girls born in 1997 (vaccine cohort) to unvaccinated girls in the baseline cohort [19]. To estimate herd effect, we compared unvaccinated girls in the vaccine cohort to unvaccinated girls in the baseline cohort. Finally, we compared vaccinated and unvaccinated girls within the vaccine cohort. Adjusting for region of residence using log-binomial regression did not change the estimates and is not included in the results section.

All tests were 2-sided, and *P* values <.05 were considered statistically significant. The data were analyzed with Stata/SE 15.0 (StataCorp) software.

RESULTS

Approximately 20% of the invited girls participated by delivering a urine sample (Table 1). We observed small differences

in participation rates between the northern, middle, western, southern, eastern, and capital regions of Norway, ranging from 19.8% to 23.1% for the 1994 cohort, from 17.0% to 20.0% for the 1996 cohort, and from 21.7% to 24.5% for the 1997 cohort. In total, 17 749 urine samples were analyzed.

Vaccine uptake was higher in participating than in all invited girls (Table 1). Among participating girls born in 1994, 1996, and 1997, 1.7%, 3.8%, and 77.0%, respectively, had received 3 doses of HPV vaccine. The mean age at first dose was higher in the 1994 and 1996 cohorts than in the 1997 cohort, but similar among invited and participating girls within each cohort (15.1, 14.6, and 12.5 years, respectively).

At the cohort level, the prevalence of any HPV type declined from 19.9% (95% CI, 18.8%–21.0%) in the baseline cohort to 11.5% (95% CI, 10.8%–12.3%) in the vaccine cohort (RR, 0.58 [95% CI, .53–.63]), corresponding to an overall reduction, irrespective of HPV type, of 42% (95% CI, 37%–47%) (Table 2). The prevalence of vaccine types declined from 7.4% (95% CI, 6.7%–8.1%) in the baseline cohort to 1.4% (95% CI, 1.1%–1.7%) in the vaccine cohort (RR, 0.19 [95% CI, .15–.24]), corresponding to a reduction of 81% (95% CI, 76%–85%). Furthermore, significant reductions were observed for combinations of non-vaccine types as well as for several single nonvaccine types, including LR types, probably/possibly HR types, and the HR types HPV-31, -33, -39, -45, -51, -52, and -59 (Table 2, Figure 1,

Table 1. Uptake of Human Papillomavirus (HPV) Vaccine by Birth Cohort and Participation Status Among 88 949 17-Year-Old Norwegian Girls Born in 1994, 1996, or 1997

Birth Year	Participation Status	Population	Initiated HPV Vaccination ^a	Completed HPV Vaccination ^b	Completed HPV Vaccination ^b , % of Those Who Initiated	Age at First Dose of HPV Vaccine, y, Mean (SD)
1994	Invited	25 811 (100)	500 (1.9)	271 (1.0)	54.2	15.2 (0.95)
	Consented to participate	6 778 (26.3)	212 (3.1)	112 (1.7)	52.8	15.2 (1.01)
	Delivered urine sample	5 528 (21.4)	186 (3.4)	96 (1.7)	51.6	15.1 (1.02)
	HPV results available	5 468 (21.2)	185 (3.4)	95 (1.7)	51.4	15.1 (1.02)
1996	Invited	31 749 (100)	1161 (3.7)	855 (2.7)	73.6	14.3 (1.12)
	Consented to participate	7 489 (23.6)	394 (5.3)	283 (3.8)	71.8	14.6 (1.12)
	Delivered urine sample	6 016 (18.9)	326 (5.4)	231 (3.8)	70.9	14.6 (1.11)
	HPV results available	5 921 (18.6)	322 (5.4)	227 (3.8)	70.5	14.6 (1.11)
1997	Invited	31 389 (100)	22 178 (70.7)	21 396 (68.2)	96.5	12.5 (0.52)
	Consented to participate	9 297 (29.6)	7 366 (79.2)	7 152 (76.9)	97.1	12.5 (0.51)
	Delivered urine sample	7 457 (23.8)	5 904 (79.2)	5 740 (77.0)	97.2	12.5 (0.51)
	HPV results available	6 360 (20.3)	5 033 (79.1)	4 899 (77.0)	97.3	12.5 (0.49)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: HPV, human papillomavirus; SD, standard deviation.

^aReceived at least 1 dose of HPV vaccine before 1 January the year urine was sampled from the birth cohort (1 January 2011 for girls born in 1994, 1 January 2013 for girls born in 1996, and 1 January 2014 for girls born in 1997).

^bReceived all 3 doses of HPV vaccine before 1 January the year urine was sampled from the birth cohort (1 January 2011 for girls born in 1994, 1 January 2013 for girls born in 1996, and 1 January 2014 for girls born in 1997).

Table 2. Human Papillomavirus (HPV) Prevalence in Urine Samples From 17-Year-Old Norwegian Girls, by Birth Cohort (N = 17749)

HPV Type	Birth Cohorts Not Eligible for Routine HPV Vaccination						Birth Cohort Eligible for Routine HPV Vaccination		
	Girls Born in 1994 (n = 5468)			Girls Born in 1996 (n = 5921)			Girls Born in 1997 (n = 6360)		
	No.	% (95% CI)	RR	No.	% (95% CI)	RR (95% CI)	No.	% (95% CI)	RR (95% CI)
Any HPV type	1087	19.9 (18.8–21.0)	1 (ref)	916	15.5 (14.6–16.4)	0.78 (.72–.84)	733	11.5 (10.8–12.3)	0.58 (.53–.63)
Any HR type ^a	611	11.2 (10.4–12.0)	1 (ref)	450	7.6 (7.0–8.3)	0.68 (.61–.76)	314	4.9 (4.4–5.5)	0.44 (.39–.50)
Any probably/possibly HR type ^b	243	4.4 (3.9–5.0)	1 (ref)	239	4.0 (3.6–4.6)	0.91 (.76–1.08)	186	2.9 (2.5–3.4)	0.66 (.55–.79)
Any LR type ^c	597	10.9 (10.1–11.8)	1 (ref)	462	7.8 (7.1–8.5)	0.71 (.64–.80)	366	5.8 (5.2–6.4)	0.53 (.47–.60)
Vaccine types									
Vaccine types ^d	403	7.4 (6.7–8.1)	1 (ref)	285	4.8 (4.3–5.4)	0.65 (.56–.76)	88	1.4 (1.1–1.7)	0.19 (.15–.24)
HPV-16 or -18	280	5.1 (4.6–5.7)	1 (ref)	189	3.2 (2.8–3.7)	0.62 (.52–.75)	73	1.1 (.9–1.4)	0.22 (.17–.29)
HPV-6 or -11	164	3.0 (2.6–3.5)	1 (ref)	121	2.0 (1.7–2.4)	0.68 (.54–.86)	20	0.3 (.2–.5)	0.10 (.07–.17)
HPV-6	150	2.7 (2.3–3.2)	1 (ref)	104	1.8 (1.5–2.1)	0.64 (.50–.82)	17	0.3 (.2–.4)	0.10 (.06–.16)
HPV-11	15	0.3 (.2–.5)	1 (ref)	17	0.3 (.2–.5)	1.05 (.53–2.07)	3	0.05 (.02–.1)	0.17 (.05–.55)
HPV-16	192	3.5 (3.1–4.0)	1 (ref)	142	2.4 (2.0–2.8)	0.68 (.55–.85)	57	0.9 (.7–1.2)	0.26 (.19–.34)
HPV-18	109	2.0 (1.7–2.4)	1 (ref)	61	1.0 (.8–1.3)	0.52 (.38–.70)	16	0.3 (.2–.4)	0.13 (.08–.21)
Nonvaccine types									
Any nonvaccine HR type	440	8.0 (7.4–8.8)	1 (ref)	330	5.6 (5.0–6.2)	0.69 (.60–.79)	256	4.0 (3.6–4.5)	0.50 (.43–.58)
Any HR type other than 16, 18, 31, 33, and 45	370	6.8 (6.1–7.5)	1 (ref)	254	4.3 (3.8–4.8)	0.63 (.54–.74)	228	3.6 (3.2–4.1)	0.53 (.45–.62)
HPV-31, -33, -45, -52, or -58	211	3.9 (3.4–4.4)	1 (ref)	176	3.0 (2.6–3.4)	0.77 (.63–.94)	98	1.5 (1.3–1.9)	0.40 (.32–.51)
HPV-31, -33, or 45	141	2.6 (2.2–3.0)	1 (ref)	132	2.2 (1.9–2.6)	0.86 (.68–1.09)	57	0.9 (.7–1.2)	0.35 (.26–.47)
HPV-31	69	1.3 (1.0–1.6)	1 (ref)	71	1.2 (1.0–1.5)	0.95 (.68–1.32)	15	0.2 (.1–.4)	0.19 (.11–.32)
HPV-33	49	0.9 (.7–1.2)	1 (ref)	50	0.8 (.6–1.1)	0.94 (.64–1.39)	27	0.4 (.3–.6)	0.47 (.30–.75)
HPV-35	11	0.2 (.1–.4)	1 (ref)	9	0.2 (.08–.3)	0.76 (.32–1.77)	16	0.3 (.2–.4)	1.25 (.59–2.65)
HPV-39	71	1.3 (1.0–1.6)	1 (ref)	33	0.6 (.4–.8)	0.43 (.29–.65)	30	0.5 (.3–.7)	0.36 (.24–.55)
HPV-45	30	0.5 (.4–.8)	1 (ref)	20	0.3 (.2–.5)	0.62 (.35–1.07)	17	0.3 (.2–.4)	0.49 (.27–.87)
HPV-51	128	2.3 (2.0–2.8)	1 (ref)	76	1.3 (1.0–1.6)	0.55 (.41–.73)	73	1.1 (.9–1.4)	0.49 (.37–.65)
HPV-52	72	1.3 (1.0–1.7)	1 (ref)	37	0.6 (.5–.8)	0.47 (.32–.70)	35	0.6 (.4–.8)	0.42 (.28–.62)
HPV-56	65	1.2 (.9–1.5)	1 (ref)	56	0.9 (.7–1.2)	0.80 (.56–1.13)	58	0.9 (.7–1.2)	0.77 (.54–1.09)
HPV-58	21	0.4 (.3–.6)	1 (ref)	15	0.3 (.2–.4)	0.66 (.34–1.26)	13	0.2 (.1–.3)	0.53 (.27–1.05)
HPV-59	79	1.4 (1.2–1.8)	1 (ref)	68	1.1 (.9–1.5)	0.79 (.58–1.10)	48	0.8 (.6–1.0)	0.52 (.37–.74)
Other									
Nonavalent HPV types ^e	541	9.9 (9.1–10.7)	1 (ref)	409	6.9 (6.3–7.6)	0.70 (.62–.79)	179	2.8 (2.4–3.3)	0.28 (.24–.34)

Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, high risk; LR, low risk; RR, relative risk.

^aHPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.

^bHPV type 26, 30, 53, 66, 67, 68, 69, 70, 73, or 82.

^cHPV type 6, 11, 40, 42, 43, 54, 61, 74, 81, 83, 86, 87, 89, 90, or 91.

^dHPV type 6, 11, 16, or 18.

^eHPV type 6, 11, 16, 18, 31, 33, 45, 52, or 58.

and [Supplementary Table 1](#)). Estimates for all of the single HPV types according to their classification in species are presented in [Supplementary Table 1](#). The proportion of HPV-positive girls with >1 HPV type declined from 46.4% (95% CI, 43.4%–49.3%) in the baseline cohort to 32.2% (95% CI, 28.9%–35.7%) in the vaccine cohort.

A significant reduction in prevalence of any HPV type as compared to the baseline cohort was also observed in the 1996 cohort (RR, 0.78 [95% CI, .72–.84]; [Table 2](#)). The prevalence of vaccine types was also significantly reduced (RR, 0.65 [95% CI, .56–.76]). Several nonvaccine-type combinations were also significantly reduced.

When comparing the vaccine cohort to the 1996 cohort, we observed a significant decline in the prevalence of any HPV

type, vaccine types, and several nonvaccine type combinations, as well as some single nonvaccine types ([Supplementary Table 2](#)).

Compared to unvaccinated girls in the baseline cohort, the prevalence of any HPV type was significantly reduced in both unvaccinated and vaccinated girls in the vaccine cohort (RR, 0.54 [95% CI, .46–.63] and 0.59 [95% CI, .54–.65], respectively; [Table 3](#)). For vaccine types, the prevalence declined from 7.7% (95% CI, 7.0%–8.4%) in unvaccinated girls in the baseline cohort to 3.5% (95% CI, 2.6%–4.6%) in unvaccinated girls and to 0.8% (95% CI, 0.6%–1.1%) in vaccinated girls born in 1997. This corresponds to a reduction of 54% (95% CI, 39%–66%) in unvaccinated and 90% (95% CI, 86%–92%) in vaccinated girls born in 1997. Among vaccinated girls born in 1997, significant




Figure 1. Type-specific human papillomavirus (HPV) prevalence with 95% confidence intervals in urine samples from 17-year-old Norwegian girls born in 1994, 1996, or 1997 (N = 17 749).

reductions in prevalence were also observed for several single nonvaccine types, including LR types, probably/possibly HR types, and the HR types 31, 33, 39, 45, 51, 52, and 59 (Figure 2). The reduction of HPV-31/33/45 combined was 68% (95% CI, 54%–77%). The reduction of nonavalent vaccine types was 76% (95% CI, 71%–80%). Significant reductions in the prevalence of several single nonvaccine types and combinations were also observed among unvaccinated girls born in 1997.

We observed no difference in the prevalence of any HPV type between vaccinated and unvaccinated girls within the vaccine cohort (RR, 1.09 [95% CI, .92–1.30]), but found a significantly lower prevalence of vaccine types in vaccinated girls (RR, 0.23 [95% CI, .15–.35]) (Table 4). A significantly higher combined prevalence of any nonvaccine HR types was seen in vaccinated as compared to unvaccinated girls born in 1997 (RR, 1.41 [95% CI, 1.02–1.97]).

In a supplementary analysis among unvaccinated girls only, we observed a significant reduction in the prevalence of any HPV type in the 1996 cohort compared with the baseline cohort and a further reduction in the vaccine cohort (RR, 0.79 [95% CI, .73–.86] and 0.54 [95% CI, .46–.63], respectively; Supplementary Table 3). Similar patterns were observed for vaccine types and several nonvaccine-type combinations.

DISCUSSION

In this large, population-based, cross-sectional study, we found a significant reduction in HPV prevalence after introduction of

the HPV vaccine in Norway. The overall reduction of any HPV type was 42%, and the reduction in vaccine types was 81% in the vaccine cohort, as compared to the baseline cohort. The total effectiveness of the HPV immunization program against vaccine types was 90%. A reduction in several nonvaccine types was also observed. The reduction of HPV-31/33/45 combined was 68%. Within the vaccine cohort, the prevalence of vaccine types was reduced by 77% in vaccinated as compared to unvaccinated girls. Significant reductions in vaccine types and several nonvaccine types were also observed in unvaccinated girls born in 1997, indicating herd effect.

A major strength of the current study is the large sample size and the population-based design. The study is one of the largest of its kind, with 17 749 samples tested for 37 HPV genotypes. The vaccine impact was assessed at age 17 years, 5 years after vaccination. In studies in cervical screening populations, vaccine impact is generally measured at a higher age.

Individual records from the Norwegian Immunisation Registry enabled linkage of HPV prevalence data to individual HPV vaccination status. Notification to the Norwegian Immunisation Registry is mandatory, and information from the electronic patient record systems is transferred electronically to the immunization registry [13]. Thus, registration is considered nearly complete.

Another strength is the high uptake of HPV vaccine in 12- to 13-year-old girls, in general not yet sexually active, and thus

Table 3. Human Papillomavirus (HPV) Prevalence in Urine Samples From Norwegian 17-Year-Old Unvaccinated and Vaccinated Girls Born in 1997 Compared to Unvaccinated Girls Born in 1994 (N = 11 479)

HPV Type	Unvaccinated ^a Girls Born in 1994 (n = 5254)			Unvaccinated ^a Girls Born in 1997 (n = 1321)			Fully Vaccinated ^b Girls Born in 1997 (n = 4904)		
	No.	% (95% CI)	RR	No.	% (95% CI)	RR (95% CI)	No.	% (95% CI)	RR (95% CI)
Any HPV type	1041	19.8 (18.8–20.9)	1 (ref)	141	10.7 (9.1–12.5)	0.54 (.46–.63)	573	11.7 (10.8–12.6)	0.59 (.54–.65)
Any HR type ^c	588	11.2 (10.4–12.1)	1 (ref)	62	4.7 (3.7–6.0)	0.42 (.32–.54)	244	5.0 (4.4–5.6)	0.44 (.38–.51)
Any probably/possibly HR type ^d	226	4.3 (3.8–4.9)	1 (ref)	30	2.3 (1.6–3.2)	0.53 (.36–.77)	153	3.1 (2.7–3.6)	0.73 (.59–.89)
Any LR type ^e	569	10.8 (10.0–11.7)	1 (ref)	69	5.2 (4.1–6.6)	0.48 (.38–.61)	288	5.9 (5.2–6.6)	0.54 (.47–.62)
Vaccine types									
Vaccine types ^f	402	7.7 (7.0–8.4)	1 (ref)	46	3.5 (2.6–4.6)	0.46 (.34–.61)	39	0.8 (.6–1.1)	0.10 (.08–.14)
HPV-16 or -18	279	5.3 (4.7–5.9)	1 (ref)	35	2.6 (1.9–3.7)	0.50 (.35–.70)	35	0.7 (.5–1.0)	0.13 (.09–.19)
HPV-6 or -11	164	3.1 (2.7–3.6)	1 (ref)	14	1.1 (.6–1.8)	0.34 (.20–.58)	5	0.1 (.04–.2)	0.03 (.01–.08)
HPV-6	150	2.9 (2.4–3.3)	1 (ref)	12	0.9 (.5–1.6)	0.32 (.18–.57)	4	0.08 (.03–.2)	0.03 (.01–.07)
HPV-11	15	0.3 (.2–.5)	1 (ref)	2	0.2 (.04–.6)	0.53 (.14–2.07)	1	0.02 (.004–.1)	0.07 (.01–.42)
HPV-16	191	3.6 (3.2–4.2)	1 (ref)	24	1.8 (1.2–2.7)	0.50 (.33–.76)	31	0.6 (.4–.9)	0.17 (.12–.25)
HPV-18	109	2.1 (1.7–2.5)	1 (ref)	11	0.8 (.5–1.5)	0.40 (.22–.74)	4	0.08 (.03–.2)	0.04 (.02–.10)
Nonvaccine types									
Any nonvaccine HR type	418	8.0 (7.3–8.7)	1 (ref)	40	3.0 (2.2–4.1)	0.38 (.28–.52)	210	4.3 (3.8–4.9)	0.54 (.46–.63)
Any HR type other than 16, 18, 31, 33, and 45	349	6.6 (6.0–7.3)	1 (ref)	34	2.6 (1.8–3.6)	0.39 (.27–.55)	189	3.9 (3.4–4.4)	0.58 (.49–.69)
HPV-31, -33, -45, -52, or 58	204	3.9 (3.4–4.4)	1 (ref)	16	1.2 (.7–2.0)	0.31 (.19–.51)	80	1.6 (1.3–2.0)	0.42 (.33–.54)
HPV-31, -33, or -45	139	2.6 (2.2–3.1)	1 (ref)	13	1.0 (.6–1.7)	0.37 (.21–.65)	42	0.9 (.6–1.2)	0.32 (.23–.46)
HPV-31	69	1.3 (1.0–1.7)	1 (ref)	8	0.6 (.3–1.2)	0.46 (.23–.94)	7	0.1 (.07–.3)	0.11 (.05–.23)
HPV-33	47	0.9 (.7–1.2)	1 (ref)	2	0.2 (.04–.6)	0.17 (.05–.63)	23	0.5 (.3–.7)	0.52 (.32–.86)
HPV-35	11	0.2 (.1–.4)	1 (ref)	0	0 (0–.3)	0 (.0001–1.39)	16	0.3 (.2–.5)	1.56 (.74–3.30)
HPV-39	64	1.2 (1.0–1.6)	1 (ref)	6	0.5 (.2–1.0)	0.37 (.17–.84)	22	0.4 (.3–.7)	0.37 (.23–.59)
HPV-45	30	0.6 (.4–.8)	1 (ref)	4	0.3 (.1–.8)	0.53 (.20–1.44)	13	0.3 (.2–.5)	0.46 (.25–.88)
HPV-51	123	2.3 (2.0–2.8)	1 (ref)	10	0.8 (.4–1.4)	0.32 (.17–.61)	61	1.2 (1.0–1.6)	0.53 (.39–.72)
HPV-52	68	1.3 (1.0–1.6)	1 (ref)	3	0.2 (.08–.7)	0.18 (.06–.53)	31	0.6 (.4–.9)	0.49 (.32–.74)
HPV-56	59	1.1 (.9–1.4)	1 (ref)	11	0.8 (.5–1.5)	0.74 (.39–1.39)	46	0.9 (.7–1.2)	0.84 (.57–1.22)
HPV-58	19	0.4 (.2–.6)	1 (ref)	1	0.08 (.01–.4)	0.21 (.04–1.23)	12	0.2 (.1–.4)	0.68 (.33–1.37)
HPV-59	76	1.4 (1.2–1.8)	1 (ref)	9	0.7 (.4–1.3)	0.47 (.24–.92)	39	0.8 (.6–1.1)	0.55 (.38–.81)
Other									
Nonavalent HPV types ^g	533	10.1 (9.4–11.0)	1 (ref)	56	4.2 (3.3–5.5)	0.42 (.32–.55)	119	2.4 (2.0–2.9)	0.24 (.20–.29)

Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, high risk; LR, low risk; RR, relative risk.

^aReceived no doses of HPV vaccine 15 days before sampling.

^bReceived 3 doses of HPV vaccine at least 15 days before sampling.

^cHPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.

^dHPV type 26, 30, 53, 66, 67, 68, 69, 70, 73, or 82.

^eHPV type 6, 11, 40, 42, 43, 54, 61, 74, 81, 83, 86, 87, 89, 90, or 91.

^fHPV type 6, 11, 16, or 18.

^gHPV type 6, 11, 16, 18, 31, 33, 45, 52, or 58.

probably HPV naive. The mean age at first vaccine dose was 12.5 years. In a recent study from Norway, only 3% of students in upper secondary school reported to have had sexual intercourse before the age of 14 [20]. No catch-up vaccination was offered in Norway until 2016, and vaccine uptake was low in age cohorts not eligible for routine HPV vaccination. Thus, the presented results are likely to reflect the effectiveness of the vaccination program in a largely HPV-naive population.

Urine sampling is noninvasive and reported to be preferred over self-collecting cervicovaginal swabs [21, 22]. In young prescreening populations, as in our study, urine sampling may provide higher response rates than self-collected genital swabs, as demonstrated in nonattenders to cervical screening at age

21 [23]. The HPV prevalence may be lower in urine samples than in cervical samples [24–26]. However, several studies have found a good agreement between HPV detected in urine and cervical samples, and urine sampling has been suggested as an adequate alternative to monitor the impact of HPV immunization programs or to increase uptake in screening [22, 25–28].

The response rate in our study was quite low, although higher than reported from similar studies in the same age group [29–31]. The low response rate may have caused selection bias. We have no information on sexual history or socioeconomic factors, and participating and nonparticipating girls may differ in these respects. We would, however, expect any association between these factors and the willingness to participate to be




Figure 2. Type-specific human papillomavirus (HPV) prevalence with 95% confidence intervals in urine samples from 17-year-old unvaccinated girls born in 1994 vs 17-year-old vaccinated girls born in 1997 (N = 10 158).

Table 4. Human Papillomavirus (HPV) Prevalence in Urine Samples From 17-Year-Old Norwegian Girls Born in 1997, by HPV Vaccination Status (N = 6225)

HPV Type	Unvaccinated ^a (n = 1321)			Fully Vaccinated ^b (n = 4904)		
	No.	% (95% CI)	RR	No.	% (95% CI)	RR (95% CI)
Any HPV type	141	10.7 (9.1–12.5)	1 (ref)	573	11.7 (10.8–12.6)	1.09 (.92–1.30)
Any HR type ^c	62	4.7 (3.7–6.0)	1 (ref)	244	5.0 (4.4–5.6)	1.06 (.81–1.39)
Any probably/possibly HR type ^d	30	2.3 (1.6–3.2)	1 (ref)	153	3.1 (2.7–3.6)	1.37 (.94–2.02)
Any LR type ^e	69	5.2 (4.1–6.6)	1 (ref)	288	5.9 (5.2–6.6)	1.12 (.87–1.45)
Vaccine types						
Vaccine types ^f	46	3.5 (2.6–4.6)	1 (ref)	39	0.8 (.6–1.1)	0.23 (.15–.35)
HPV-16 or -18	35	2.6 (1.9–3.7)	1 (ref)	35	0.7 (.5–1.0)	0.27 (.17–.43)
HPV-6 or -11	14	1.1 (.6–1.8)	1 (ref)	5	0.1 (.04–.2)	0.10 (.04–.26)
HPV-6	12	0.9 (.5–1.6)	1 (ref)	4	0.08 (.03–.2)	0.09 (.03–.26)
HPV-11	2	0.2 (.04–.6)	1 (ref)	1	0.02 (.004–.1)	0.13 (.02–1.03)
HPV-16	24	1.8 (1.2–2.7)	1 (ref)	31	0.6 (.4–.9)	0.35 (.21–.59)
HPV-18	11	0.8 (.5–1.5)	1 (ref)	4	0.08 (.03–.2)	0.10 (.03–.29)
Nonvaccine types						
Any nonvaccine HR type	40	3.0 (2.2–4.1)	1 (ref)	210	4.3 (3.8–4.9)	1.41 (1.02–1.97)
Any HR type other than 16, 18, 31, 33, and 45	34	2.6 (1.8–3.6)	1 (ref)	189	3.9 (3.4–4.4)	1.50 (1.05–2.14)
HPV-31, -33, -45, -52, or 58	16	1.2 (.7–2.0)	1 (ref)	80	1.6 (1.3–2.0)	1.35 (.80–2.28)
HPV-31, -33, or -45	13	1.0 (.6–1.7)	1 (ref)	42	0.9 (.6–1.2)	0.87 (.47–1.60)
HPV-31	8	0.6 (.3–1.2)	1 (ref)	7	0.1 (.07–.3)	0.24 (.09–.62)
HPV-33	2	0.2 (.04–.6)	1 (ref)	23	0.5 (.3–.7)	3.1 (.81–11.85)
HPV-35	0	0 (0–.3)	1 (ref)	16	0.3 (.2–.5)	...
HPV-39	6	0.5 (.2–1.0)	1 (ref)	22	0.4 (.3–.7)	0.99 (.41–2.37)
HPV-45	4	0.3 (.1–.8)	1 (ref)	13	0.3 (.2–.5)	0.88 (.30–2.55)
HPV-51	10	0.8 (.4–1.4)	1 (ref)	61	1.2 (1.0–1.6)	1.64 (.86–3.16)
HPV-52	3	0.2 (.08–.7)	1 (ref)	31	0.6 (.4–.9)	2.78 (.91–8.57)
HPV-56	11	0.8 (.5–1.5)	1 (ref)	46	0.9 (.7–1.2)	1.13 (.59–2.15)
HPV-58	1	0.08 (.01–.4)	1 (ref)	12	0.2 (.1–.4)	3.23 (.54–19.37)
HPV-59	9	0.7 (.4–1.3)	1 (ref)	39	0.8 (.6–1.1)	1.17 (.58–2.37)
Other						
Nonavalent HPV types ^g	56	4.2 (3.3–5.5)	1 (ref)	119	2.4 (2.0–2.9)	0.57 (.42–.78)

Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, high risk; LR, low risk; RR, relative risk.

^aReceived no doses of HPV vaccine 15 days before sampling

^bReceived 3 doses of HPV vaccine at least 15 days before sampling

^cHPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.

^dHPV type 26, 30, 53, 66, 67, 68, 69, 70, 73, or 82.

^eHPV type 6, 11, 40, 42, 43, 54, 61, 74, 81, 83, 86, 87, 89, 90, or 91.

^fHPV type 6, 11, 16, or 18.

^gHPV type 6, 11, 16, 18, 31, 33, 45, 52, or 58.

similar across the invited birth cohorts. The recruitment procedure was identical for all birth cohorts. The median age at first in Norway, intercourse has been stable in the period 2002–2017 [20, 32, 33]. Thus, we believe that the comparisons between birth cohorts are valid.

The HPV vaccine uptake was higher in participants than in nonparticipants. However, in several previous studies, including one with Norwegian data, no association between HPV vaccination and sexual behavior was seen [30, 34–37]. The vast majority of HPV-vaccinated girls in our study were vaccinated before becoming sexually active, further reducing the probability of an association between HPV vaccination and sexual behavior. Nevertheless, due to possible selection bias, we cannot rule out the possibility that unvaccinated and vaccinated participants in our study differ with regard to sexual behavior. If non-sexually active unvaccinated girls were more willing to participate than sexually active unvaccinated girls, the measured HPV prevalence in unvaccinated girls would be lower than in the total unvaccinated population of girls born in 1997. This could partly explain the slightly higher prevalence of non-vaccine types observed in vaccinated as compared to unvaccinated girls born in 1997. Given such selection bias, the vaccine effectiveness would be underestimated, whereas the herd effect would be overestimated.

Samples from the baseline cohort were collected in 2011, 2 years into the HPV immunization program. The girls in the first vaccine-eligible birth cohort were only 14 years old in 2011. We therefore believe the herd effect in the 3-years-older unvaccinated baseline cohort to be minimal.

The HPV prevalence in the 2 nonvaccine-eligible cohorts is comparable to findings in urine samples from 15- to 18-year-old girls in Scotland, prior to HPV vaccine introduction [29]. Other population-based studies in similar age groups have reported somewhat higher prevalence of any HPV type, but lower prevalence of vaccine types in self-collected cervical samples [30, 38].

We observed a substantial reduction in HPV vaccine types, consistent with reports from other countries [3, 4, 6, 39–41]. Moreover, in line with previous studies [3, 4, 6], we found a strong herd effect in unvaccinated girls.

Previous meta-analyses, including data on both quadrivalent and bivalent vaccine, have found evidence of cross-protection against HPV-31 or the combination HPV-31/33/45 [3, 5], whereas a slight increase in HPV-39 and -52 was found in one meta-analysis [5]. Cross-protection against HPV-31, -33, -35, -45, and -52 has been reported for the bivalent vaccine [6, 41]. We observed significant reduction in several single nonvaccine types, including LR types, probably/possibly HR types, and the HR types HPV-31, -33, -39, -45, -51, -52, and -59, both when comparing the vaccine cohort to the baseline cohort and when comparing vaccinated girls in the 1997 cohort to unvaccinated girls in the baseline cohort. The observed reduction of nonvaccine types may be due to changes

in sexual behavior, natural variation, cross-protection, or unknown causes. There is no indication of a change in sexual behavior in Norway during recent years [20, 32, 33]. Natural variation may explain some of the decline in HPV types where cross-protection has previously not been suggested. However, natural variation alone seems unlikely to have caused such a large reduction, in particular for vaccine types and known cross-protective types. Alternatively, the reduction of non-vaccine types could be linked to the absence of HPV-16/18, which is known to impair the immune response in the cervix, in particular through depletion of Langerhans cells [42, 43]. The reduction could also be attributable to vaccine-induced cross-reactivity of CD4 T-helper cells, as suggested in an earlier study [44]. They observed a significant reduction in HPV-6, -11, and -74 in HPV-naïve girls and women vaccinated with bivalent vaccine, not targeting HPV-6/11. Although a higher level of cell-mediated immune response has been found for the bivalent AS04 adjuvanted vaccine than for the quadrivalent vaccine [45], our findings may suggest a role for cross-protective cellular immunity in naïve cohorts vaccinated with non-AS04 adjuvanted vaccines.

Interestingly, we also observed a significant reduction in several single nonvaccine types in unvaccinated girls in the vaccine cohort, suggesting a possible cross-protective herd effect, also reported for the bivalent vaccine [6].

As previously reported, we also observed a significant reduction in HPV prevalence in the 1996 cohort [12]. Given the large herd protection in unvaccinated girls, it seems likely that the reduction in HPV prevalence in the 1996 cohort, at least partially, is caused by herd effect, and not entirely by natural fluctuation in the occurrence of HPV. Girls born in 1996 are only 1 year older than the first vaccine-eligible cohort, and urine samples were collected in 2013, 4 years into the vaccination program.

We observed no indication of type replacement after the introduction of the HPV immunization program in Norway, in line with recent findings from Scotland [6]. This must, however, be followed closely over the coming years as more birth cohorts enter the program.

Although the prevalence of vaccine types was lower among vaccinated than unvaccinated girls within the 1997 cohort, no difference in prevalence of any HPV type was observed, as previously reported [31, 40]. A slightly higher prevalence of some nonvaccine types was observed in vaccinated compared with unvaccinated girls in the 1997 cohort. However, in both groups the prevalence was significantly lower than in unvaccinated girls in the baseline cohort. Similar findings were recently reported in Australia [40]. This may be explained by unmasking of nonvaccine types due to lack of primer competition in the PCR assay in the absence of HPV-16/18 in samples from vaccinated girls [40, 46].

The prevalence of multiple infections was high, consistent with findings from other studies [47, 48], but declined following

vaccination. The interplay between multiple HPV infections and changes in HPV prevalence following introduction of HPV vaccination programs warrants further investigation.

CONCLUSIONS

Single-cohort delivery of HPV vaccine to 12- to 13-year-old girls was associated with a reduction in vaccine types of 90% in vaccinated and 54% in unvaccinated girls in the first vaccine-eligible cohort 5 years after vaccination. A substantial reduction in nonvaccine types was observed in both vaccinated and unvaccinated girls, suggesting cross-protection and herd effect. No indication of type replacement was observed. The early impact of the HPV immunization program in this largely HPV-naïve Norwegian population seems more beneficial than anticipated upon introduction of the vaccine in 2009, but more effectiveness studies in HPV-naïve populations are needed to confirm the findings. With the growing amount of evidence for sustained long-term protection of HPV vaccine [49, 50], we feel optimistic that the observed reduction in HPV prevalence in urine samples may translate into a future decline in the incidence of precancerous lesions and cervical cancer in Norway.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. We thank all of the study participants. We are also thankful to Patricia Schreuder, Nina Hovland, Erna Davidsen (deceased), Ranveig Heiberg Andersen, and Grethe Karin Eriksen at the Norwegian Institute of Public Health (NIPH) for their support in the recruitment of study participants; Ole-Martin Kvinge at NIPH for data management; the Department of Biobanks at NIPH, in particular Nina Kristin Stensrud, Kari Harbak, Kaja Klykken Aas, Gholam Davarpanah, Olive Oliva, and Rolf Erik Kolstad for distribution of sampling kits, receipt, and processing of urine samples; and Ellen Myrvang, Alexander Eieland, and Nermin Zecic at the HPV Reference Laboratory for technical support with HPV genotyping.

Financial support. This work was supported by the NIPH and the Norwegian Ministry of Health and Care Services.

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents. IARC **2012**; 100:1–441.
2. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. *Best Pract Res Clin Obstet Gynaecol* **2018**; 47:14–26.
3. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis* **2015**; 15:565–80.
4. Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. *Clin Infect Dis* **2016**; 63:519–27.
5. Meshor D, Soldan K, Lehtinen M, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. *Emerg Infect Dis* **2016**; 22:1732–40.
6. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. *Lancet Infect Dis* **2017**; 17:1293–302.
7. Cameron RL, Kavanagh K, Cameron Watt D, et al. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap. *J Epidemiol Community Health* **2017**; 71:954–60.
8. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. *Nat Rev Clin Oncol* **2013**; 10:400–10.
9. Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. *Best Pract Res Clin Obstet Gynaecol* **2018**; 47:42–58.
10. Bergsaker M, Ege MS, Hagerup-Jenssen M, Seterelv SS, Stålcrautz J, Wiklund B. The Childhood Immunisation Programme in Norway. Report for 2013 [in Norwegian]. Oslo: Norwegian Institute of Public Health, **2014**. <https://www.fhi.no/publ/2014/barnevaksinasjonsprogrammet-i-norge/>. Accessed 24 April 2018.
11. Norwegian Institute of Public Health. Statistics on HPV vaccination in the childhood immunisation programme [in Norwegian]. <https://www.fhi.no/hn/helseregistre-og-registre/sysvak/dekkningsstatistikk/>. Accessed 24 April 2018.
12. Molden T, Feiring B, Ambur OH, et al. Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: a nationwide cross-sectional study of three non-vaccinated birth cohorts. *Papillomavirus Res* **2016**; 2:153–8.

13. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register—SYSVAK. *Euro Surveill* **2012**; 17. pii:20147. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20147>.
14. Norwegian Institute of Public Health. Statistics from the Norwegian Prescription Database. <http://www.norpd.no/Prevalens.aspx>. Accessed 24 April 2018.
15. Söderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. *J Clin Microbiol* **2009**; 47:541–6.
16. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. *J Clin Microbiol* **2006**; 44:504–12.
17. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. *Stat Med* **1998**; 17:857–72.
18. Fagerland MW, Lydersen S, Laake P. Recommended confidence intervals for two independent binomial proportions. *Stat Methods Med Res* **2015**; 24:224–54.
19. Halloran ME. Overview of vaccine field studies: types of effects and designs. *J Biopharm Stat* **2006**; 16:415–27.
20. Bakken A. Ungdata. Nasjonale resultater 2017. Norwegian Social Research report 10/17 [in Norwegian]. Oslo: NOVA, **2017**. <http://www.hioa.no/Om-HiOA/Senter-for-velferds-og-arbeidslivsforskning/NOVA/Publikasjoner/Rapporter/2017/Ungdata-2017>. Accessed 24 April 2018.
21. Senkomago V, Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. *J Clin Virol* **2016**; 74:26–31.
22. Franciscatto LG, Silva CM, Barcellos RB, et al. Comparison of urine and self-collected vaginal samples for detecting human papillomavirus DNA in pregnant women. *Int J Gynaecol Obstet* **2014**; 125:69–72.
23. Sinka K, Lacey M, Robertson C, et al. Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring. *Sex Transm Infect* **2011**; 87:548–52.
24. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. *Eur J Clin Microbiol Infect Dis* **2012**; 31:627–40.
25. Enerly E, Olofsson C, Nygård M. Monitoring human papillomavirus prevalence in urine samples: a review. *Clin Epidemiol* **2013**; 5:67–79.
26. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. *BMJ* **2014**; 349:g5264.
27. Cuschieri K, Nandwani R, McGough P, et al. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. *J Med Virol* **2011**; 83:1983–7.
28. Van Keer S, Tjalma WAA, Pattyn J, et al. Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. *Eur J Clin Microbiol Infect Dis* **2018**; 37:859–69.
29. O’Leary MC, Sinka K, Robertson C, et al. HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. *Br J Cancer* **2011**; 104:1221–6.
30. Jacot-Guillarmod M, Pasquier J, Greub G, Bongiovanni M, Achtari C, Sahli R. Impact of HPV vaccination with Gardasil in Switzerland. *BMC Infect Dis* **2017**; 17:790.
31. Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE. High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women. *J Infect Dis* **2018**; 217:1579–89.
32. Træen B, Stigum H, Magnus P. Rapport fra seksualvaneundersøkelsene i 1987, 1992, 1997 og 2002 [in Norwegian]. Oslo: Norwegian Institute of Public Health, **2003**. <https://www.fhi.no/publ/eldre/rapport-fra-seksualvane-undersokels/>. Accessed 2 July 2018.
33. Jensen KE, Munk C, Sparen P, et al. Women’s sexual behavior. Population-based study among 65 000 women from four Nordic countries before introduction of human papillomavirus vaccination. *Acta Obstet Gynecol Scand* **2011**; 90:459–67.
34. Bednarczyk RA, Davis R, Ault K, Orenstein W, Omer SB. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. *Pediatrics* **2012**; 130:798–805.
35. Forster AS, Marlow LA, Stephenson J, Wardle J, Waller J. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. *Vaccine* **2012**; 30:4939–44.
36. Hansen BT, Kjær SK, Arnheim-Dahlström L, et al. Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: evidence from a large survey of Nordic women. *Vaccine* **2014**; 32:4945–53.
37. Smith LM, Kaufman JS, Strumpf EC, Lévesque LE. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. *CMAJ* **2015**; 187:E74–81.
38. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. *JAMA* **2007**; 297:813–9.
39. Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. *Clin Infect Dis* **2016**; 63:1281–7.

40. Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination. *J Infect Dis* **2018**; 217:1590–600.
41. Woestenberg PJ, King AJ, van Benthem BHB, et al. Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. *J Infect Dis* **2018**; 217:213–22.
42. Matthews K, Leong CM, Baxter L, et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. *J Virol* **2003**; 77:8378–85.
43. Moerman-Herzog A, Nakagawa M. Early defensive mechanisms against human papillomavirus infection. *Clin Vaccine Immunol* **2015**; 22:850–7.
44. Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. *J Infect Dis* **2013**; 208:1391–6.
45. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. *Hum Vaccin* **2011**; 7:1359–73.
46. Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. *Am J Epidemiol* **2013**; 178:625–34.
47. Chaturvedi AK, Katki HA, Hildesheim A, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. *J Infect Dis* **2011**; 203:910–20.
48. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. *Br J Cancer* **2014**; 110:2804–11.
49. Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. *BMJ Open* **2017**; 7:e015867.
50. Kjaer SK, Nygård M, Dillner J, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. *Clin Infect Dis* **2018**; 66:339–45.